Amylyx Pharmaceuticals Stock (NASDAQ: AMLX)

Dernières nouvelles pour Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

AMYLYX PHARMACEUTICALS INC

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

Trading Ideas

FTRK

Fast Track Group Shares Halted On Circuit Breaker To The Downside, Stock Now Down -38.4%

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Buy and maintains $26 price target.

News

Price Target

Reiteration

Analyst Ratings

Larimar Therapeutics, Inc. - Common Stock

LRMR

Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $26 Price Target

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and raises the price target from $50 to $54.

BBIO

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $54

Canaccord Genuity analyst Kingsley Crane maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and raises the price target from $4.25 to $4.6.

Canaccord Genuity Maintains Hold on BlackBerry, Raises Price Target to $4.6

B of A Securities analyst Nicholas Thomas maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy and raises the price target from $30 to $31.

B of A Securities Maintains Buy on Carnival, Raises Price Target to $31

Guggenheim analyst Michael Schmidt reiterates Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Buy and maintains $80 price target.

RVMD

Guggenheim Reiterates Buy on Revolution Medicines, Maintains $80 Price Target

SRFM

Surf Air Mobility Shares Resume Trade

Wells Fargo analyst Michael Turrin maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and raises the price target from $565 to $585.

MSFT

Wells Fargo Maintains Overweight on Microsoft, Raises Price Target to $585

Guggenheim analyst Michael Morris maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $725 to $840.

SPOT

Guggenheim Maintains Buy on Spotify Technology, Raises Price Target to $840

Digital assets security provider Ledger on Wednesday announced it has integrated Chorus One's MEV Max Vault into its Ledger Live platform, giving users direct access to optimized Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) staking rewards. 
The partnership enables Ledger Live users to stake and unstake ETH through Chorus One's MEV Max without leaving the Ledger Live app.
This move expands ETH staking options to Ledger's large user base, with more than seven million Ledger devices sold globally and approximately 20% of the world's crypto assets secured through the company's hardware.
The MEV Max Vault is designed to maximize staking yields by leveraging advanced infrastructure, close collaboration with Ethereum block builders, and proprietary research strategies. 
According to Chorus One, MEV Max has consistently delivered higher returns than standard Ethereum staking products, with recent examples including block captures that earned 159.9 and 134 ETH, respectively.
Ledger Live users can now access Chorus One's MEV Max staking interface via the platform's &#8220;Earn&#8221; and &#8220;Discover&#8221; sections, allowing seamless ETH staking within Ledger's secure environment. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46077689/polymarket-reportedly-looking-to-raise-200-million-at-1b-valuation">Polymarket Reportedly Looking To Raise $200 Million At $1B Valuation</a>
The integration is part of a broader effort to streamline the crypto staking process and offer more intuitive, user-friendly tools to the mainstream market.
Additional features such as the minting of osETH, a liquid staking token enabling DeFi participation and re-staking, are under consideration for future updates. 
Chorus One and Ledger are also exploring more advanced staking functionalities, including looped staking.
Brian Crain, CEO of Chorus One, emphasized the importance of improving accessibility and usability, stating, &#8220;It's now on us to create products and services that are seamless and intuitive. What we're doing with Ledger is a major step toward that vision.&#8221;
By embedding MEV Max staking directly into Ledger Live, the partnership is aiming to reduce the complexity often associated with staking and decentralized finance (DeFi) tools. 
Both companies see the move as a step toward making Ledger Live a more comprehensive financial hub for crypto users.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46075963/wealthy-investors-want-crypto-advice-but-doubt-their-advisors-experience-report">Wealthy Investors Want Crypto Advice But Doubt Their Advisors&#8217; Experience: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Can Ledger's MEV Max Vault Boost Your ETH Rewards? What Crypto Stakers Need To Know

B of A Securities analyst Jessica Reif Ehrlich maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $60 to $65.

FOXA

B of A Securities Maintains Buy on Fox, Raises Price Target to $65

Wells Fargo analyst Christian Wetherbee maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Equal-Weight and raises the price target from $220 to $235.

Wells Fargo Maintains Equal-Weight on FedEx, Raises Price Target to $235

Wells Fargo analyst Jason Haas maintains Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) with a Overweight and raises the price target from $63 to $65.

Wells Fargo Maintains Overweight on Rollins, Raises Price Target to $65

Guggenheim analyst Michael Morris maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $60 to $62.

Guggenheim Maintains Buy on Fox, Raises Price Target to $62

Wells Fargo analyst Richard Garchitorena maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Overweight and raises the price target from $98 to $105.

Wells Fargo Maintains Overweight on CF Industries Holdings, Raises Price Target to $105

Urgent.ly Shares Resume Trade

Surf Air Mobility Shares Halted On Circuit Breaker To The Upside, Stock Now Up 40%

<a href="https://www.bloomberg.com/news/articles/2025-06-25/google-debuts-gemini-ai-coding-tool-in-bid-to-entice-developers">https://www.bloomberg.com/news/articles/2025-06-25/google-debuts-gemini-ai-coding-tool-in-bid-to-entice-developers</a>

General

GOOG

GOOGL

'Google Debuts Gemini AI Coding Tool in Bid to Entice Developers'- Bloomberg

Wells Fargo analyst Michael Blum maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Overweight and raises the price target from $253 to $267.

Wells Fargo Maintains Overweight on Cheniere Energy, Raises Price Target to $267

Wells Fargo analyst Michael Blum maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underweight and raises the price target from $59 to $61.

Wells Fargo Maintains Underweight on Cheniere Energy Partners, Raises Price Target to $61

Press Releases

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Comments

Amylyx Pharmaceuticals

Actualités

Dernières nouvelles pour Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL